TR-Dizin İndeksli Yayınlar Koleksiyonu
Permanent URI for this collectionhttps://hdl.handle.net/20.500.14627/9
Browse
3 results
Search Results
Article Lactobacillus Rhamnosus GG Alleviates Bisphenol-A Induced Oxidative Stress in Serum(Marmara University, Faculty of Pharmacy, 2025) Şener, Göksel; Tunali-Akbay, Tugba; Dorucu, Dogancan; Ede-Pazarbasi, Seren; Dede, Pınar; Ede-Pazarbas, SerenThe objective of this investigation was to identify changes in the serum oxidant-antioxidant balance of rats exposed to bisphenol A (BPA) and to investigate the impact of Lactobacillus rhamnosus GG (LGG) administration on those changes. Twenty-four rats (Wistar Albino, 250-300 grams, male) were divided into control, BPA, and BPA+LGG groups with an equal number of rats. BPA and LGG were applied to the rats in the relevant groups for six weeks, five days each week. Six weeks later, the blood samples were withdrawn and serum samples were prepared. Total oxidant and antioxidant status (TAS), glutathione, and lipid peroxidation determinations were determined in serum samples, and the oxidative stress index was calculated. BPA exposure decreased serum total antioxidant status and increased serum total oxidative status, oxidative stress index, and lipid peroxidation level compared to the control group. LGG administration improved the increased serum oxidative stress caused by BPA. Administration of LGG to BPA-treated rats reversed oxidative stress-induced changes. In conclusion, administration of Lactobacillus rhamnosus GG to rats for 30 consecutive days prevented oxidative stress in serum caused by bisphenol A.Review Citation - WoS: 3Citation - Scopus: 4Oral Pharmabiotic Tablet Formulations(Marmara Univ, 2024) Kandur, Buse; Ugurlu, Timucin; Rayaman, Erkan; Ahbaz, Sevinc S.; Şahbaz, SevinçPharmabiotic is a unique and recent term used to describe formulations containing probiotics. Pharmabiotics are probiotics prepared in a pharmaceutical form used to treat diseases and disorders by making physicochemical changes in human health. Probiotics, prebiotics, and synbiotics are included in this scope, and enzobiotics, which are a rising class of supplements, should be evaluated in this context, as they are a subspecies of synbiotics. Pharmabiotics, unlike nutribiotics, do not necessarily contain live microorganisms. The best examples of these are paraprobiotics and postbiotics. Tablet formulations are suitable dosage forms for pharmabiotics due to their redundant superiority over other solid dosage forms. Tablets are frequently preferred because they can be produced at low cost, are easily transported, and modified, are suitable for large-scale production, and are more stable than other dosage forms. Considering the examples in the literature and the definition of pharmabiotic, several tablet formulations can be mentioned as pharmabiotics. They can be divided into conventional uncoated tablets, chewable tablets, and effervescent tablets. With recent studies, this classification has expanded, and buccal mucoadhesive tablets, ODTs (orally disintegrating tablets) and FDTs (fast disintegrating tablets), layered/multi-layered tablets, and tablets within tablets have also taken their place in the classification. This article focuses on oral tablet formulations that can be classified as pharmabiotics.Review The Use of Probiotics in the Treatment and Prophylaxis of Various Diseases in Turkiye: a Systematic Review(Bilimsel Tip Yayinevi, 2023) Kilbas, Elmas Pinar Kahraman; Altindis, MustafaThe aim of this study is to analyze the available information on the use of probiotics containing different microorganisms, singly or in combination, in order to investigate the effect of probiotics on the treatment, prophylaxis and microbiota of various diseases. In addition to Pubmed, Google Scholar, SCOPUS, EMBASE, Cochrane Library of Systematic Reviews, CINAHL, AMED, Turkish Medline electronic da- tabases, the gray literature was searched to cover the years 2004-2021. Randomized controlled studies (RCTs) included in the specified selection criteria were brought together. RCTs were evaluated using the Cochrane risk of bias tool. Of the 32 RCTs included in total, only yeast (Saccharomyces spp.) was administered in fourteen, only Lactobacillus spp. in six, Bifidobacterium spp. only in four, and probiotic supplementation containing more than one bacterial strain in six. Only 10/32 of the included studies fully reported the probiotic strain, and 22/32 reported only at the species level. In all nine studies using probiotics for the treatment of diarrhea, probiotics were reported to shorten the duration of diarrhea and length of hospital stay. Four of the five studies reporting the use of probiotics in the treatment of necrotizing enterocolitis reported that probiotics were not effective in reducing the incidence of necrotizing enterocolitis, but could improve nutritional tolerance. In two of the four RCTs investigating the use of probiotics in the treatment of Helicobacter pylori infec- tion, it was stated that the side effects associated with eradication therapy decreased. In both studies conducted for prophylaxis, it was reported that probiotics prevent antibiotic-associated diarrhea. This study shows that probiotics have positive results for the treatment indications and prophylaxis of various diseases. For the sustainability of these health benefits and the safe administration of probiotics, more research is needed that includes strain information and side effect reports.